Baxdrostat is a novel, orally active aldosterone synthase (CYP11B2) inhibitor. Baxdrostat reduces aldosterone production by highly selective inhibition of aldosterone synthase, thereby lowering blood pressure[1-2]. Baxdrostat can be used in research related to resistant hypertension and primary aldosteronism[3-4].
References:
[1] Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025 Oct 9;393(14):1363-1374.
[2] Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405.
[3] Dey S, Frishman WH, Aronow WS. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension. Cardiol Rev. 2025 May-Jun 01;33(3):243-245.
[4] Dogra S, Shah S, Gitzel L, et al. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension. Curr Probl Cardiol. 2023 Nov;48(11):101918.
Baxdrostat 是一种新型的、具有口服活性的醛固酮合成酶（CYP11B2）抑制剂。Baxdrostat通过高选择性抑制醛固酮合成酶来减少醛固酮的生成，从而降低血压[1-2]。Baxdrostat可用于难治性高血压和原发性醛固酮增多症的相关研究[3-4]。